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Immunology SelectThe inflammatory response—characterized by release of cytokines such as TNFa and IL-1b and infiltration of infected or
injured tissue by macrophages and neutrophils—is the first line of defense against infection by pathogens. Although an
early inflammatory response is beneficial in stemming the tide of infection, a prolonged response may result in severe
illness or even death. For example, the 1918 Spanish influenza virus was lethal because it triggered a ‘‘cytokine storm’’
that resulted in severe lung damage. An inappropriate and prolonged inflammatory response to normal nonpathogenic
gut bacteria is a cause of Crohn’s disease. Meanwhile, insidious low-level inflammation in the tumor microenvironment
aids and abets tumor cells in their quest to become metastatic. Understanding the triggers of inflammation and the
signaling pathways involved in cytokine production and immune cell mobilization will be essential for developing thera-
peutics to treat diseases caused by a runaway inflammatory response.
Metastasis Proceeds at More Than a Snail’s Pace
Inflammation in the tumor microenvironment—characterized by the infiltration of macrophages and the release of proinflam-
matory cytokines such as TNFa—is a powerful driver of tumor formation and metastasis. The ability of tumor cells to detach
from their microenvironment and migrate to other locations is reminiscent of the change that takes place during embryogen-
esis when epithelial cells become more fibroblast-like and start to migrate. This process, termed the epithelial-to-mesen-
chymal transition (EMT), is characterized by loss of expression of a surface marker called E-cadherin that enables cells to
adhere to the substratum. The transcription factor Snail is responsible for repressing expression of E-cadherin. Reporting
in Cancer Cell, Wu et al. (2009) now pinpoint Snail as a principal culprit in the inflammation-driven metastasis of tumor cells.
They discovered that the normally labile Snail protein becomes stabilized in response to TNFa released by macrophages loi-
tering at the invasive edge of epithelial tumors. The stable Snail protein then switches on genes required for instigation of the
EMT program, enabling epithelial tumors to acquire a more mesenchymal phenotype that facilitates their detachment and
migration into the circulation. Snail is normally phosphorylated by GSK3b and is then ubiquitinated and degraded by
the proteasome, but how does Snail become stabilized? The authors show that TNFa switches on expression of the master
transcription factor NF-kB, which then activates a gene encoding CSN2, a component of the COP9 signaling complex (signal-
osome) that regulates ubiquitin ligases. The authors speculate that Snail may bind to the signalosome shielding itself from
phosphorylation or that it may be deubiquitinated by this complex thus avoiding degradation. To test their model, the authors
blocked expression of Snail in breast tumor cells; they then injected these cells into the tail vein of SCID mice treated with
lipopolysaccharide to induce an inflammatory response. They found that the number of breast tumor metastases in the
lung was greatly decreased when Snail expression was blocked. These new findings strengthen the connection between
inflammation and tumor metastasis and pinpoint CSN as a potential new target for anticancer drug development.
Wu et al. (2009). Cancer Cell 15, 416–428.
The Sweet Dulcet Sounds of Gene Silencing
Macrophagesand theTNFa that theyproducearealso thestarattractionof anewstudy that
seeks to blockmacrophage-mediated inflammation using small-interferingRNAs (siRNAs).
There has beenmuch interest in using siRNAs to block the expression of genes involved in
various diseases, but efforts havebeen stymiedby the challenge of delivering the siRNAs to
specific target cells. Reporting in Nature, Aouadi et al. (2009) now demonstrate that by
packaging siRNAs directed against TNFa into ‘‘sugar-coated’’ particles and giving them
orally to mice, they can reduce the inflammatory response to lipopolysaccharidemediated
by TNFa. The key to their success is the design of the carrier particles, which are basically
yeast cells missing their cytoplasm andmost of their polysaccharide coat. After subjecting
the yeast cells to a seriesof alkaline and solvent extractions, the authorswere leftwith shells
composed of little other than b1, 3-D-glucan. These shells were loaded with siRNAs
directed against TNFa and fed to mice. The siRNA particles were eagerly ingested by
macrophages in the gut-associated lymphatic tissue that then wandered off throughout
the body ensuring that the gene silencing effect would be global not local. Shells carrying
as little as 20 mg/kg of siRNA oligonucleotides were sufficient to decrease expression of
TNFa by up to 80% in the peritoneal macrophages of treated mice. Perhaps the biggest
surprise came when the authors subjected macrophages to a screen for inflammation
geneexpression. Theydiscovered a newmediator of TNFa action calledmitogen-activated
protein kinase kinase kinase kinase (Map4k4). When mice were fed particles filled with siRNAs directed against the gene en-
coding this signalingmolecule, therewasdecreasedproductionof TNFa andanother proinflammatory cytokine IL-1b, ensuring
that themice did notmount an inflammatory response to lipopolysaccharide. This fascinating study not only provides evidence
supporting theefficiencyof a newdeliverymode for siRNAsbut also identifies a new therapeutic target,Map4k4, for developing
drugs to treat inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and diabetes.
M. Aouadi et al. (2009). Nature 458, 1182–1184.
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A NOD to Unraveling Crohn’s Disease
Between 30% and 50% of patients with an inflammatory bowel disorder called Crohn’s
disease carry mutations in the gene encoding the NOD2 receptor. NOD2 is an intracel-
lular bacterial sensor (or so-called pattern recognition receptor) that binds to a distinct
motif in bacterial peptidoglycans resulting in activation of the inflammatory response.
There are several mouse models of Crohn’s disease. In one model, mice lack an anti-
inflammatory cytokine called IL-10, which is known to modulate the inflammatory
response in mucosal tissues including the gut. These animals develop severe colitis
when exposed to normal nonpathogenic gut bacteria, closely mimicking the disease
process in humans. However, there has been conflicting data from the different mouse
models, and it remains unclear how impaired function of NOD2 and decreased IL-10
production are connected in the pathogenesis of Crohn’s disease. In newwork published
inNature Immunology, Noguchi et al. (2009) now clarify this connection usingmonocytes
from Crohn’s disease patients carrying a specific mutation (3020insC) in NOD2 that
results in partial loss of the leucine-rich repeat domain of the receptor. These investiga-
tors show that monocytes from Crohn’s disease patients with this mutation produce far
less IL-10 when resting or after stimulation with peptidoglycan compared with mono-
cytes from healthy individuals. But how could a defective NOD2 receptor result in the
downregulation of IL-10 production? The answer lies with a molecule called heteroge-
neous nuclear ribonucleoprotein A1 (hnRNP-A1), which binds to the promoter of the
IL-10 gene in monocytes from healthy individuals but not those from Crohn’s disease
patients with the 3020insC mutation. The authors demonstrate that the 3020insC NOD2 mutant protein but not wild-type
NOD2 blocks phosphorylation of hnRNP-A1 by p38 kinase. This phosphorylation step is required for hnRNP-A1 to bind to
the IL-10 locus and to switch on expression of this gene. Delineating the elusive connection between IL-10 and NOD2 should
provide new therapeutic opportunities not only for treating Crohn’s disease but also for treating graft-versus-host disease,
which is also associated with the 3020insC mutation in NOD2.
E. Noguchi et al. (2009). Nat. Immunol. 10, 471–479.
Influenza Virus: A Cytokine Storm in a Teacup?
Pattern recognition sensors belonging to the NLR family are important in fighting the
flu. Influenza A virus strains cause seasonal flu, but occasionally extremely virulent
strains appear that result in catastrophic pandemics such as the 1918 Spanish flu,
which killed 50 million people worldwide. A feature of the Spanish flu that made it
so deadly was a dramatic inflammatory response to the virus culminating in a rapid
‘‘cytokine storm’’ that resulted in severe lung tissue damage and death. Two new
studies (Allen et al., 2009; Thomas et al., 2009) in Immunity now examine the details
of how the influenza A virus triggers the inflammatory response in mice. The two
groups show that the RNA of influenza A viruses is recognized by the pattern recog-
nition receptor NLRP3 expressed by macrophages. NLRP3 then orchestrates the
assembly of a large protein signaling complex (the inflammasome) that activates the protease caspase-1. Caspase-1, in
turn, drives production of the proinflammatory cytokines IL-1b and IL-18 from precursor molecules, leading to infiltration
of tissue by neutrophils and macrophages and an inflammatory response. Next the investigators analyzed mice lacking
NLRP3 or caspase-1, which cannot produce IL-1b and thus mount a limited inflammatory response to influenza virus infec-
tion. To their surprise, they found that these mice, unlike their wild-type cousins, suffered severe lung injury and even death,
suggesting that IL-1bmay have a protective effect. The investigators propose that by attractingmacrophages and neutrophils
to infected lung tissue, IL-1b helps to control the infection and to limit lung damage. Thus, a carefully managed inflammatory
response may be beneficial in fighting influenza virus during the early stages of infection, although prolonged inflammation of
lung tissue may ultimately benefit the virus and hasten the host’s demise. The authors propose that finding ways to enhance
the function of the NLRP3 inflammasome could be a new therapeutic option for treating the flu.
I.C. Allen et al. (2009). Immunity 30, 556–565.
P.G. Thomas et al. (2009). Immunity 30, 566–575.
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